数字健康应用 (DiGA) 用于治疗抑郁症和泛性焦虑障碍:系统健康应用审查和公布证据系统审查的协议
Annika Schmitz1, Lucas Kueppers1, Jacob Klein1
1Institute of General Practice and Family Medicine, University Hospital Bonn, Bonn, Germany.
JMIR research protocols
|July 10, 2025
概括
本系统性审查评估了德国数字健康应用程序 (DiGAs) 对于抑郁和焦虑. 这些发现将指导DiGA的使用和开发,以改善患者护理.
科学领域:
- 数字健康数字健康
- 心理健康技术 心理健康技术
- 基于证据的医学基于证据的医学.
背景情况:
- 抑郁症和通用焦虑障碍 (GAD) 是普遍存在的精神健康状况,具有重大影响.
- 认知行为疗法 (CBT) 是一种常见的治疗方法,但由于成本和人员短缺,获得治疗方法受到限制.
- 德国在2020年率先为数字健康应用程序 (DiGAs) 提供报销,但医生仍然持怀疑态度.
研究的目的:
- 系统地审查德国对抑郁症和GAD的DIGAs.
- 评估上市的DiGAs的指导方针合规性,功能和可用性.
- 综合来自随机对照试验的DiGA有效性和质量的证据.
主要方法:
- 协议遵循PRISMA 2015指南,并且是PROSPERO注册的.
- 包括一个系统的健康应用程序审查 (IMS,MARS) 和一个系统的RCT文献审查.
- 采用PRISMA,IMS应用程序功能评分系统,MARS,RoB2和GRADE的方法来进行全面的评估.
主要成果:
- 系统的文献搜索于2024年7月至8月进行,计划于2025年11月进行更新.
- 数据提取,合成和评估预计将于2026年春季完成.
- 结果将通过PRISMA流程图和表格呈现,详细介绍DiGA信息,偏差风险和整体质量.
结论:
- 该审查将为当前的DiGA使用和未来的发展提供信息.
- 高质量的特征可以促进医生信任和透明度.
- 识别质量缺陷将引导制造商和机构使用DiGA改进患者护理.
相关概念视频
01:30Generalized Anxiety Disorder
200
Generalized Anxiety Disorder (GAD) is a chronic condition characterized by excessive and uncontrollable worry that persists for at least six months, significantly interfering with daily functioning. Unlike situational anxiety, which arises in response to specific stressors, GAD often occurs without a clear cause. Individuals may experience disproportionate worry about work, health, or relationships. For instance, a person might continuously fear poor health despite normal medical evaluations or...
200
01:23Antidepressant Drugs: MAOIs and Other Agents
337
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
337
01:18Depression: Overview
331
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
331
01:27Depressive Disorders: MDD and Dysthymia
207
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
207
01:28Drug Therapy
96
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
96
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
562
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
562